A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2018
At a glance
- Drugs FDL 169 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Flatley Discovery Lab
- 31 Aug 2018 Biomarkers information updated
- 11 Apr 2018 Status changed from recruiting to completed.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.